Company: TVRD
Filing Date: 2025-10-07
Form Type: S-1/A
Source: 0001104659-25-097519
Chunk: 330

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-07
Form: S-1/A
Chunk 330
---
unallocated) (1)       | ​ |                    |     969 | ​ |      |   4,373 |
| TTI-109                                              | ​ |                    |   1,193 | ​ |      |   1,466 |
| Unallocated research and development expense:        | ​ |                    |         | ​ |      |         |
| Personnel costs                                      | ​ |                    |   2,988 | ​ |      |   2,900 |
| Consultant fees and other costs (2)                  | ​ |                    |   1,032 | ​ |      |   1,144 |
| General and administrative expense:                  | ​ |                    |         | ​ |      |         |
| Personnel costs                                      | ​ |                    |   2,085 | ​ |      |   1,882 |
| Other general and administrative expenses (3)        | ​ |                    |   2,372 | ​ |      |     917 |
| Interest income                                      | ​ |                    |    -747 | ​ |      |  -1,318 |
| Other (income) expense, net                          | ​ |                    |   2,037 | ​ |      |       — |
| Net loss                                             | ​ |                  $ | -29,397 | ​ |    $ | -17,347 |

| (1) | Pre-clinical, CMC, and other (unallocated) costs includes pre-clinical testing, CMC, and other direct research and development expenses that are not allocated to a specific program. |

| (2) | Consultant fees and other costs includes expenses incurred for research and development consultants as well as payroll costs for employees within the research and development function. |

| (3) | Other general and administrative expenses include professional fees, accounting services, rent, and other overhead and administrative expenses. |

Assets provided to the CODM are consistent with those reported on the balance sheets.

F-28

18.Related-party Transactions During the years ended December 31, 2024 and 2023, the Company did not have any transactions with related parties. The Company evaluates transactions with counterparties who may be considered related parties, including owners, members of management or affiliates and then discloses the nature and amounts of those transaction in the notes to its financial statements. 19.Subsequent Events Management has evaluated all subsequent events through April 1, 2025, which was the date the financial statements were available to be issued